Gujarat Terce Laboratories Share Price
Sector: Biotechnology & Drugs
53.00 +1.85 (3.62%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
49.65
Today’s High
53.99
52 Week Low
44.52
52 Week High
94.90
Key Metrics
- Market Cap (In Cr) 39.4
- Beta 0.39
- Div. Yield (%) 0
- P/B 6.07
- TTM P/E -
- Sector P/E 22.43
- D/E 0
- Open Price 49.65
- Prev Close 51.15
Gujarat Terce Laboratories Analysis
Price Analysis
-
1 Week-5.56%
-
3 Months-13.31%
-
6 Month-34.19%
-
YTD-37.5%
-
1 Year10.3%
Risk Meter
- 63% Low risk
- 63% Moderate risk
- 63% Balanced Risk
- 63% High risk
- 63% Extreme risk
Gujarat Terce Laboratories News
Q4 results today: GIC, Aurobindo Pharma, Sumitomo Chemical, Nazara Tech, more
1 min read . 26 May 2025Gujarat Terce Laboratories Q3 FY24 Results: Revenue Increased by 9.37% YoY & Profit at ₹0.67Cr
1 min read . 08 Feb 2024Gujarat Terce Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 50.2
- Selling/ General/ Admin Expenses Total
- 16.19
- Depreciation/ Amortization
- 0.38
- Other Operating Expenses Total
- 11.21
- Total Operating Expense
- 46.7
- Operating Income
- 3.5
- Net Income Before Taxes
- 3.39
- Net Income
- -0.98
- Diluted Normalized EPS
- -1.31
- Period
- 2025
- Total Assets
- 22.83
- Total Liabilities
- 16.35
- Total Equity
- 6.48
- Tangible Book Valueper Share Common Eq
- 8.73
- Period
- 2025
- Cashfrom Operating Activities
- 3.06
- Cashfrom Investing Activities
- 0.46
- Cashfrom Financing Activities
- -2.83
- Net Changein Cash
- 0.69
- Period
- 2024
- Total Revenue
- 47.97
- Selling/ General/ Admin Expenses Total
- 15.78
- Depreciation/ Amortization
- 0.37
- Other Operating Expenses Total
- 13.24
- Total Operating Expense
- 47.08
- Operating Income
- 0.9
- Net Income Before Taxes
- 0.54
- Net Income
- 0.24
- Diluted Normalized EPS
- 0.33
- Period
- 2024
- Total Assets
- 23.27
- Total Liabilities
- 16.17
- Total Equity
- 7.11
- Tangible Book Valueper Share Common Eq
- 9.58
- Period
- 2024
- Cashfrom Operating Activities
- 2.6
- Cashfrom Investing Activities
- -0.46
- Cashfrom Financing Activities
- -4.08
- Net Changein Cash
- -1.94
- Period
- 2023
- Total Revenue
- 46.78
- Selling/ General/ Admin Expenses Total
- 20.84
- Depreciation/ Amortization
- 0.36
- Other Operating Expenses Total
- 8.75
- Total Operating Expense
- 49.31
- Operating Income
- -2.52
- Net Income Before Taxes
- -2.89
- Net Income
- -1.67
- Diluted Normalized EPS
- -2.25
- Period
- 2023
- Total Assets
- 28.53
- Total Liabilities
- 21.66
- Total Equity
- 6.86
- Tangible Book Valueper Share Common Eq
- 9.25
- Period
- 2023
- Cashfrom Operating Activities
- 0.03
- Cashfrom Investing Activities
- 0.62
- Cashfrom Financing Activities
- -0.12
- Net Changein Cash
- 0.52
- Period
- 2022
- Total Revenue
- 40.13
- Selling/ General/ Admin Expenses Total
- 15.83
- Depreciation/ Amortization
- 0.28
- Other Operating Expenses Total
- 7.94
- Total Operating Expense
- 39.29
- Operating Income
- 0.84
- Net Income Before Taxes
- 0.75
- Net Income
- 0.87
- Diluted Normalized EPS
- 1.18
- Period
- 2022
- Total Assets
- 27.39
- Total Liabilities
- 18.86
- Total Equity
- 8.53
- Tangible Book Valueper Share Common Eq
- 11.5
- Period
- 2022
- Cashfrom Operating Activities
- -0.44
- Cashfrom Investing Activities
- -2.37
- Cashfrom Financing Activities
- 1.53
- Net Changein Cash
- -1.28
- Period
- 2021
- Total Revenue
- 25.18
- Selling/ General/ Admin Expenses Total
- 12.97
- Depreciation/ Amortization
- 0.18
- Other Operating Expenses Total
- 4.99
- Total Operating Expense
- 28.12
- Operating Income
- -2.94
- Net Income Before Taxes
- -2.53
- Net Income
- -2.52
- Diluted Normalized EPS
- -3.4
- Period
- 2021
- Total Assets
- 21.8
- Total Liabilities
- 14.14
- Total Equity
- 7.66
- Tangible Book Valueper Share Common Eq
- 10.33
- Period
- 2021
- Cashfrom Operating Activities
- -0.17
- Cashfrom Investing Activities
- -0.42
- Cashfrom Financing Activities
- 1.84
- Net Changein Cash
- 1.24
- Period
- 2020
- Total Revenue
- 37.54
- Selling/ General/ Admin Expenses Total
- 15.13
- Depreciation/ Amortization
- 0.24
- Other Operating Expenses Total
- 7.83
- Total Operating Expense
- 37.1
- Operating Income
- 0.44
- Net Income Before Taxes
- 0.44
- Net Income
- 0.28
- Diluted Normalized EPS
- 0.37
- Period
- 2020
- Total Assets
- 22.34
- Total Liabilities
- 11.23
- Total Equity
- 11.11
- Tangible Book Valueper Share Common Eq
- 14.97
- Period
- 2020
- Cashfrom Operating Activities
- -1.59
- Cashfrom Investing Activities
- -0.27
- Cashfrom Financing Activities
- 1.72
- Net Changein Cash
- -0.14
- Period
- 2019
- Total Revenue
- 31.03
- Selling/ General/ Admin Expenses Total
- 12.82
- Depreciation/ Amortization
- 0.21
- Other Operating Expenses Total
- 5.7
- Total Operating Expense
- 30.76
- Operating Income
- 0.27
- Net Income Before Taxes
- 0.35
- Net Income
- 0.43
- Diluted Normalized EPS
- 0.58
- Period
- 2019
- Total Assets
- 19.34
- Total Liabilities
- 8.5
- Total Equity
- 10.83
- Tangible Book Valueper Share Common Eq
- 14.6
- Period
- 2019
- Cashfrom Operating Activities
- -0.61
- Cashfrom Investing Activities
- -0.13
- Cashfrom Financing Activities
- 0.2
- Net Changein Cash
- -0.55
- Period
- 2025-03-31
- Total Revenue
- 12.32
- Selling/ General/ Admin Expenses Total
- 4.17
- Depreciation/ Amortization
- 0.1
- Other Operating Expenses Total
- 1.6
- Total Operating Expense
- 11.37
- Operating Income
- 0.95
- Net Income Before Taxes
- 0.97
- Net Income
- -3.39
- Diluted Normalized EPS
- -4.57
- Period
- 2025-03-31
- Total Assets
- 22.83
- Total Liabilities
- 16.35
- Total Equity
- 6.48
- Tangible Book Valueper Share Common Eq
- 8.73
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 3.06
- Cashfrom Investing Activities
- 0.46
- Cashfrom Financing Activities
- -2.83
- Net Changein Cash
- 0.69
- Period
- 2024-12-31
- Total Revenue
- 12.68
- Selling/ General/ Admin Expenses Total
- 3.98
- Depreciation/ Amortization
- 0.1
- Other Operating Expenses Total
- 3.13
- Total Operating Expense
- 11.69
- Operating Income
- 0.99
- Net Income Before Taxes
- 0.98
- Net Income
- 1.01
- Diluted Normalized EPS
- 1.36
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 13.3
- Selling/ General/ Admin Expenses Total
- 4.21
- Depreciation/ Amortization
- 0.09
- Other Operating Expenses Total
- 3.22
- Total Operating Expense
- 11.73
- Operating Income
- 1.57
- Net Income Before Taxes
- 1.51
- Net Income
- 1.48
- Diluted Normalized EPS
- 2
- Period
- 2024-09-30
- Total Assets
- 24.84
- Total Liabilities
- 15.98
- Total Equity
- 8.86
- Tangible Book Valueper Share Common Eq
- 11.94
- Period
- 2024-09-30
- Cashfrom Operating Activities
- -2.16
- Cashfrom Investing Activities
- 0.23
- Cashfrom Financing Activities
- 1.93
- Net Changein Cash
- 0
- Period
- 2024-06-30
- Total Revenue
- 11.89
- Selling/ General/ Admin Expenses Total
- 3.84
- Depreciation/ Amortization
- 0.09
- Other Operating Expenses Total
- 3.27
- Total Operating Expense
- 11.9
- Operating Income
- -0.01
- Net Income Before Taxes
- -0.07
- Net Income
- -0.08
- Diluted Normalized EPS
- -0.1
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 12.21
- Selling/ General/ Admin Expenses Total
- 0.42
- Depreciation/ Amortization
- 0.09
- Other Operating Expenses Total
- 5.66
- Total Operating Expense
- 11.3
- Operating Income
- 0.91
- Net Income Before Taxes
- 0.84
- Net Income
- 0.54
- Diluted Normalized EPS
- 0.76
- Period
- 2024-03-31
- Total Assets
- 23.27
- Total Liabilities
- 16.17
- Total Equity
- 7.11
- Tangible Book Valueper Share Common Eq
- 9.58
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 2.6
- Cashfrom Investing Activities
- -0.46
- Cashfrom Financing Activities
- -4.08
- Net Changein Cash
- -1.94
- Period
- 2023-12-31
- Total Revenue
- 13.02
- Selling/ General/ Admin Expenses Total
- 5.01
- Depreciation/ Amortization
- 0.09
- Other Operating Expenses Total
- 2.94
- Total Operating Expense
- 12.26
- Operating Income
- 0.76
- Net Income Before Taxes
- 0.67
- Net Income
- 0.67
- Diluted Normalized EPS
- 0.91
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Gujarat Terce Laboratories Technical
Moving Average
SMA
- 5 Day55.08
- 10 Day55.68
- 20 Day54.77
- 50 Day56.75
- 100 Day63.58
- 300 Day70.69
Gujarat Terce Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Chandra Bhagat Pharma
- 52.3
- -5.7
- -9.83
- 90
- 46.15
- 39.46
- Medico Intercontinental
- 39.48
- 1.38
- 3.62
- 63.59
- 34
- 38.58
- Gujarat Terce Laboratories
- 53
- 1.85
- 3.62
- 94.9
- 44.52
- 39.4
- Gujarat Inject Kerala
- 24.55
- -0.61
- -2.42
- 29.12
- 13.11
- 35.81
- Veerhealth Care
- 18.54
- 0.26
- 1.42
- 27
- 9.29
- 36.94
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Chandra Bhagat Pharma
- 50.88
- 1.46
- 3.13
- 0.72
- Medico Intercontinental
- 7.53
- 0.78
- 14.32
- 4.72
- Gujarat Terce Laboratories
- -
- 5.86
- -10.41
- -1.93
- Gujarat Inject Kerala
- 35.94
- 2.84
- 9.82
- 4.14
- Veerhealth Care
- 91.4
- 1.65
- 3.01
- 4.24
Gujarat Terce Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 26-May-25
- Audited Results & Others
- 04-Feb-25
- Quarterly Results
- 28-Oct-24
- Quarterly Results & A.G.M.
- 09-Aug-24
- Quarterly Results & A.G.M.
- 29-May-24
- Audited Results
- 29-Mar-24
- Preferential issue of shares
- 05-Feb-24
- Quarterly Results
- 08-Nov-23
- Quarterly Results
- 11-Aug-23
- Quarterly Results
- 13-May-23
- Audited Results
- Meeting Date
- Announced on
- Purpose
- 17-Sept-24
- 09-Aug-24
- AGM
- 25-Aug-23
- 08-Jun-23
- AGM
- 07-Sept-21
- 24-Jun-21
- AGM



